A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
A phase 1/2 trial of CRB-701 in advanced solid tumours, run by Corbus Pharmaceuticals Inc., now recruiting.
Overview
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors is a phase 1/2 interventional study registered as NCT06265727 by Corbus Pharmaceuticals Inc., with 348 participants planned, started 2024-04-01 and due to reach its primary completion in 2027-01-16. Interventions recorded: CRB-701 and Anti-PD-1.
Similar pages
not linked directly; found by shared links- TrialFirst-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Shares Corbus Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAuger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.